Drugs / Tebipenem
Tebipenem
Trials 2 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT05296382 | Apr → Jun 2022 | — | Hartford Hospital | Completed | No outcome recorded |
| Phase 1 | NCT04919954 | Jul 2021 → Aug 2022 | bacterial infectious disease, diabetes mellitus, skin infection | Hartford Hospital | Completed | No outcome recorded |
Also used as a comparator or background therapy in 1 trial
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 4 | NCT07236944 Comparator | Dec 2025 → Mar 2029 expected | bacterial urinary tract infection | Uppsala University | Recruiting | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | tebipenem | “and 4) tebipenem (if approved by the EMA).” NCT07236944 ↗ |
| Known as | SPR994 | “This study will determine the tissue penetration of a broad-spectrum orally bioavailable carbapenem, tebipenem pivoxil hydrobromide (SPR994) (Spero Therapeutics, Inc.), into...” NCT04919954 ↗1“The purpose of this study is to measure the amount of the antibiotic, tebipenem (SPR994) that is bioavailable after crushing the tablet and administering through a feeding tube...” NCT05296382 ↗ |
| Known as | tebipenem pivoxil hydrobromide | “This study will determine the tissue penetration of a broad-spectrum orally bioavailable carbapenem, tebipenem pivoxil hydrobromide (SPR994) (Spero Therapeutics, Inc.), into...” NCT04919954 ↗ |
| Modality | Small molecule | “a broad-spectrum orally bioavailable carbapenem” NCT04919954 ↗ |
| Route | Oral | “administered orally” NCT04919954 ↗ |